Crestone had the opportunity to showcase its innovative research at two prestigious conferences: the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia. These presentations highlighted CRS3123, a narrow spectrum agent designed for the treatment of Clostridioides difficile infection (CDI). Attendees were given insights into the key differentiating features of CRS3123, as well as Phase 1 data and Phase 2 topline results. For more details on these groundbreaking findings, interested individuals are encouraged to view the event poster for an in-depth look at Crestone’s advancements.
